Compounded semaglutide: why it is not worth the risk
Compounded semaglutide is not a licensed medicine and is not legally available in Ireland. It is mixed by a facility rather than manufactured by an approved pharmaceutical process, which means no regulator has assessed its quality, purity, potency or sterility. Documented harms include overdoses requiring hospital treatment, caused by people drawing the wrong volume from a vial, and products containing semaglutide salt forms that were never tested in humans. The saving is real. So is the reason the saving exists.
What compounding actually means
Pharmacy compounding is a legitimate and long-established practice. It exists so a pharmacist can prepare something an individual patient needs that is not available commercially: a liquid version for a child who cannot swallow tablets, or a formulation free of an allergen.
That is not what is happening with GLP-1s. Here, facilities are producing large volumes of a copy of a patented medicine and selling it to people who simply want it cheaper. The word compounding is doing a lot of reputational work it has not earned, borrowing credibility from a practice this bears very little resemblance to.
Why regulators object
A licensed medicine has passed through a chain of controls that is invisible when it works and catastrophic when it is missing.
- Purity and potency testing on every batch, against a specification.
- Sterility assurance, because this is injected.
- Stability data, establishing how long it lasts and at what temperature.
- Traceability, so a specific batch can be identified.
- Recall machinery, so a faulty batch can be pulled from the market.
- Pharmacovigilance, so side effects are collected and acted on.
A compounded product has none of these. If a batch is wrong, there is no mechanism to find out and no mechanism to tell anyone.
The salt form problem
This one is specific and it is not widely understood.
A significant proportion of compounded products have been found to contain semaglutide sodium or semaglutide acetate rather than the semaglutide base used in licensed medicines. These are chemically different substances. They have not been tested in humans, their absorption and potency have not been characterised, and nobody knows whether a given amount delivers the same effect.
This is not a technicality. A product sold as semaglutide, at a stated strength, may be delivering an unknown dose of a related but different compound.
Documented harms
The clearest pattern is dosing errors, and the mechanism is straightforward.
A licensed pen delivers a measured dose through a dial. A compounded vial requires the user to calculate a volume and draw it into a syringe. When the concentration is unfamiliar or the instructions are unclear, people draw ten times the intended amount. Regulators in several jurisdictions have documented cases of exactly this, producing severe nausea and vomiting, fainting, dehydration and hospital admission.
There have also been findings of contamination, incorrect strengths and products with no detectable active ingredient at all.
The legal position in Ireland
Compounded semaglutide is not an authorised medicine in Ireland or anywhere in the European Union. It cannot be lawfully sold here, and importing prescription medicines for personal use without a prescription is illegal.
The HPRA detains substantial quantities of falsified medicines each year, and GLP-1 products have featured prominently in recent enforcement. Some falsified pens have been found to contain insulin instead of semaglutide, which is a genuinely dangerous substitution capable of causing severe hypoglycaemia in someone not expecting it.
There is no reliable way to identify a falsified product by looking at it. Packaging is copied well. Price is the most consistent signal, and it is not a good one to rely on.
Why the US situation confuses things
A lot of the material circulating online is American, and the American position was different for a period.
When semaglutide and tirzepatide were in official shortage in the United States, compounding was temporarily permitted under specific provisions. Once the shortages were resolved, that permission was withdrawn and enforcement resumed. That window is why so much content exists presenting compounded GLP-1s as a normal option.
It was never lawful in Ireland, at any point, and the EU has no equivalent shortage provision.
If cost is the actual problem
It usually is, and it is a reasonable problem to have. There are legitimate routes worth exhausting first.
Check whether the Long Term Illness Scheme applies, which covers diabetes medicines with no income test. Register for the Drugs Payment Scheme, which caps a household at €80 a month across all prescribed medicines. Ask your prescriber whether a different licensed treatment suits your circumstances at a lower cost. And compare pharmacy prices, because the spread between Irish pharmacies on the same pack is larger than most people expect.
Compounded semaglutide: common questions
No. Compounded semaglutide is not an authorised medicine in Ireland or anywhere in the European Union, and it cannot be lawfully sold here. Importing prescription medicines for personal use without a prescription is also illegal.
No. Beyond having no regulatory approval, testing or traceability, many compounded products contain semaglutide sodium or semaglutide acetate rather than the semaglutide base used in licensed medicines. These are chemically different substances that have not been tested in humans.
Documented harms include overdoses from drawing the wrong volume out of a vial, causing severe vomiting, fainting, dehydration and hospital admission. There have also been findings of contamination, incorrect strengths, and products containing no active ingredient.
While semaglutide and tirzepatide were in official shortage in the US, compounding was temporarily permitted under specific provisions. That permission was withdrawn once the shortages resolved. There was never an equivalent allowance in Ireland or the EU.
You generally cannot by looking, because packaging is copied well. Price is the most consistent signal. Falsified pens found in circulation have contained insulin instead of semaglutide, which can cause severe hypoglycaemia in someone not expecting it.
Check whether the Long Term Illness Scheme applies if you have diabetes, register for the Drugs Payment Scheme which caps a household at 80 euro a month, ask your prescriber about alternative licensed treatments, and compare pharmacy prices, which vary more than most people expect.